Press release / Newsletter
Stockholm 5 November 2020
DSruptive gets green light for clinical study of health sensing implants
DSruptive, the implant design company, has received a green light from the Swedish Ethical Review Authority (“Etikprövningsmyndigheten”) to undertake a clinical study of the company’s first-generation health sensing implants.
The study is made in cooperation with Karolinska Institutet in Stockholm. Karolinska Institutet is one of the world’s foremost medical universities and is Sweden’s single largest centre of medical academic research.
The study is scheduled to take place in early 2021.
Hannes Sjöblad, Managing Director of DSruptive, commented:
“Completing a study in a clinical setting is an important step for validating and documenting the capabilities of our subdermal health sensing platform. We are seeing a significant interest in our technology, and when the study is completed our platform will be available for a range of different clinical trials.”
For further questions contact:
Hannes Sjöblad, Managing Director
DSruptive is a design agency with expertise in implantable microelectronics and related technologies. DSruptive has developed a proprietary platform for frictionless health logging and remote diagnostics. The platform can, among numerous other applications, be used for early detection of fever both on an individual and on a population level.
About Nordic Group
Nordic Group is a company group at the forefront of healthcare innovation and personalised medicine. The group includes a range of companies and brands supporting the advancement of healthcare innovation, including Nordic Clinic, Nordic Labs, Nordic Health, Athgene, DNA-Life, Medcheck, Resistomap and Thermocheck.